ImmunityBio, Inc.IBRXNASDAQ
Loading
Year-over-year SG&A expense growth
| Period | Value |
|---|---|
| Q4 2025 | 15.24% |
| Q3 2025 | -22.46% |
| Q2 2025 | 29.66% |
| Q1 2025 | -21.75% |
| Q4 2024 | 16.19% |
| Q3 2024 | -27.08% |
| Q2 2024 | 17.59% |
| Q1 2024 | 26.50% |
| Q4 2023 | 4.07% |
| Q3 2023 | -0.63% |
| Q2 2023 | 19.03% |
| Q1 2023 | 9.51% |
| Q4 2022 | 37.72% |
| Q3 2022 | 18.21% |
| Q2 2022 | -61.60% |
| Q1 2022 | 40.77% |
| Q4 2021 | -5.79% |
| Q3 2021 | -8.69% |
| Q2 2021 | -28.34% |
| Q1 2021 | 438.73% |
| Q4 2020 | -57.11% |
| Q3 2020 | 6.81% |
| Q2 2020 | 93.27% |
| Q1 2020 | 11.34% |
| Q4 2019 | 111.83% |
| Q3 2019 | -3.75% |
| Q2 2019 | -27.17% |
| Q1 2019 | 9.45% |
| Q4 2018 | -45.24% |
| Q3 2018 | -29.53% |
| Q2 2018 | -4.92% |
| Q1 2018 | 6.82% |
| Q4 2017 | 0.03% |
| Q3 2017 | -5.29% |
| Q2 2017 | -12.94% |
| Q1 2017 | 3.27% |
| Q4 2016 | -35.66% |
| Q3 2016 | -14.57% |
| Q2 2016 | 7.27% |
| Q1 2016 | -64.39% |